Genelux Corporation (NASDAQ:GNLX – Get Free Report) insider Yong Yu sold 9,683 shares of the company’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.75, for a total transaction of $26,628.25. Following the completion of the sale, the insider directly owned 258,688 shares in the company, valued at $711,392. This trade represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Yong Yu also recently made the following trade(s):
- On Tuesday, August 4th, Yong Yu sold 653 shares of Genelux stock. The stock was sold at an average price of $2.94, for a total value of $1,919.82.
Genelux Trading Down 1.9%
Shares of NASDAQ GNLX traded down $0.05 during trading on Wednesday, reaching $2.55. 158,117 shares of the company traded hands, compared to its average volume of 366,336. The stock has a market cap of $115.36 million, a P/E ratio of -2.97 and a beta of 0.57. The firm’s fifty day simple moving average is $2.83 and its 200 day simple moving average is $2.78. Genelux Corporation has a 12-month low of $2.29 and a 12-month high of $8.53.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on GNLX. Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Genelux from a “strong sell” rating to a “sell” rating in a report on Sunday, August 23rd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.
Read Our Latest Report on Genelux
Institutional Trading of Genelux
Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Genelux in the second quarter valued at about $1,323,000. Geode Capital Management LLC raised its stake in shares of Genelux by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 381,407 shares of the company’s stock valued at $1,664,000 after acquiring an additional 27,567 shares during the period. Bank of America Corp DE purchased a new stake in shares of Genelux in the 2nd quarter valued at approximately $990,000. Flputnam Investment Management Co. acquired a new position in shares of Genelux in the 2nd quarter worth approximately $697,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Genelux in the 2nd quarter worth approximately $686,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.
Genelux Company Profile
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.
Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.
Read More
- Five stocks we like better than Genelux
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
